BFS
JUNO

Bradley Foster & Sargent’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bradley Foster & Sargent’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,445
Closed -$270K – 366
2015
Q1 		$270K Buy
+4,445
New +$216K 0.01% 313

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Bradley Foster & Sargent's JUNO Position: Q2 2015 in Review

Bradley Foster & Sargent sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2015, closing a stake of 4,445 shares — an estimated $270K sold.

Bradley Foster & Sargent first reported a position in JUNO in Q1 2015 and held it in 1 quarter. The position peaked at $270K in Q1 2015. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

  • Bradley Foster & Sargent reported no remaining Juno Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Bradley Foster & Sargent sold 4,445 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $270K.
  • Bradley Foster & Sargent first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Bradley Foster & Sargent's Juno Therapeutics, Inc. position peaked at $270K in Q1 2015.
  • 154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on Bradley Foster & Sargent's 13F filing for Q2 2015, filed 10 Aug 2015.